The antibody is directed against the CD4 antigen on rat T cells and macrophages. The specificity is the same as that of W3/25, though their binding is non-competitive. OX-35 will compete with OX-36.
| Institute |
|---|
| Medical Research Council; University of Oxford |
| Cat. #: | 156593 |
|---|---|
| Unit size: | 100 ug |
| Application: | FACS ; IHC |
| Target: | CD4 |
| Reactivity: | Rat |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | The antibody is directed against the CD4 antigen on rat T cells and macrophages. The specificity is the same as that of W3/25, though their binding is non-competitive. OX-35 will compete with OX-36. |
|---|---|
| Conjugation: | Unconjugated |
| Immunogen: | T blasts prepared in mixed lymphocyte reactions with purified rat T helper cells against irradiated spleen |
| Myeloma used: | NS0/1 |
| Target background: | The antibody is directed against the CD4 antigen on rat T cells and macrophages. The specificity is the same as that of W3/25, though their binding is non-competitive. OX-35 will compete with OX-36. |
|---|
| Format: | Liquid |
|---|---|
| Shipping conditions: | Dry ice |
| References: |
Jefferies et al. 1985. J Exp Med. 162(1):117-27. PMID: 3159821. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151015 | Anti-CyclinA [E70.1] |
Key Info
Anti-CyclinA [E70.1]
|
View Tool | |||||||||||||||||||
| 151033 | Anti-HSVUL42 [13C9] |
Key Info
Anti-HSVUL42 [13C9]
|
View Tool | |||||||||||||||||||
| 151017 | Anti-MBP [R29.6] |
Key Info
Anti-MBP [R29.6]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.